See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
MLS
Baseball
Donald Trump
Hockey
Tennis
Israel-Hamas Conflict
Hamas
Ukraine War
Published • loading... • Updated

Study explores microbiome reboot to prolong effect of Crohn's disease therapy

Summary by Medical Xpress
A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods. However, the exact reasons why this is helpful were previously unclear.

4 Articles

All
Left
Center
2
Right
Science DailyScience Daily

Microbiome as a potential key to better treatment: Clinical study on new therapy for Crohn's disease

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods. However, the exact reasons why this is helpful were previously unclear. Researchers have now been able to decipher the mechanism behind this dietary therapy.

·United States
Read Full Article
News MedicalNews Medical

Study explores microbiome reboot to prolong effect of Crohn's disease therapy

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods. However, the exact reasons why this is helpful were previously unclear.

·United States
Read Full Article
Medical XpressMedical Xpress

Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods. However, the exact reasons why this is helpful were previously unclear.

Read Full Article
hcplive.comhcplive.com

Long-Term VIVID-2 Data for Mirikizumab in Crohn’s Disease, with Edward Barnes, MD, MPH

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hcplive.com broke the news in on Monday, February 10, 2025.
Sources are mostly out of (0)

Similar News Topics

Disease

Disease

Science

Science

Diet

Diet

News
For You
Search
BlindspotLocal